Close
Back to BRPA Stock Lookup

(BRPA) – PRNewswire

Aug 16, 2021 09:32 PM NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update
May 25, 2021 06:48 AM NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)
Apr 28, 2021 02:12 PM NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia
Apr 26, 2021 09:35 AM Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team
Apr 19, 2021 03:57 PM NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development
Apr 6, 2021 01:01 AM NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
Mar 29, 2021 01:05 AM /C O R R E C T I O N -- NeuroRx/
Mar 29, 2021 01:05 AM NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
Mar 26, 2021 09:35 AM NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure
Mar 9, 2021 10:19 AM NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration
Feb 23, 2021 01:11 PM NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal O
Feb 9, 2021 08:13 AM NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19
Feb 9, 2021 07:30 AM NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critica
Jan 11, 2021 01:00 AM NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial
Dec 30, 2020 01:00 AM NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

Back to BRPA Stock Lookup